Tolvaptan and Voriconazole interaction

Tolvaptan and Voriconazole: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Voriconazole label · effective 2026-06-02

Major

…dihydroergotamine) • Finerenone • Ivabradine • Lurasidone • Naloxegol • Pimozide • Quinidine • Rifabutin [see Clinical Pharmacology (12.3) ] • Sirolimus [see Clinical Pharmacology (12.3) ] • Tolvaptan • Venetoclax: Coadministration at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…

Contraindicationsnames TolvaptanView label on DailyMed
Major

…Contraindicated Naloxegol (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Risk of Adverse Reactions Contraindicated Tolvaptan (CYP3A4 Inhibition) Although Not Studied Clinically, Voriconazole is Likely to Significantly Increase the Plasma Concentrations of Tolvaptan Contraindicated Lurasidone (CYP3A4…

Drug interactionsnames TolvaptanView label on DailyMed

From the Tolvaptan (SAMSCA) label · effective 2026-05-07

Major

…dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS [see Warnings and Precautions (5.2) ] Unable to sense or respond to thirst Hypovolemic hyponatremia Taking strong CYP3A inhibitors [see Warnings and Precautions (5.5) ] Anuria Hypersensitivity (e.g., anaphylactic shock, rash generalized) to tolvaptan or any components of the product [see Adverse…

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use of strong CYP3A inhibitors ( 4 )

Contraindicationsby drug classView label on DailyMed
Major

Avoid use with moderate to strong CYP3A inhibitors ( 5.5 )

Warnings and precautionsby drug classView label on DailyMed
Major

Do not use SAMSCA with strong inhibitors of CYP3A [see Contraindications (4) ] and avoid concomitant use with moderate CYP3A inhibitors.

Warnings and precautionsby drug classView label on DailyMed
Major

Avoid concomitant use with: Moderate CYP3A inhibitors ( 7.1 )

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.